Quarterly report pursuant to Section 13 or 15(d)

SEGMENT INFORMATION (Tables)

v3.20.1
SEGMENT INFORMATION (Tables)
6 Months Ended
Apr. 30, 2020
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
 

For the six Months Ended

April 30,

 
 

2020

 

2019

Net loss:

 

 

 

 

 

CAR-T Therapeutics

$

(1,125,363)

 

$

(3,517,219)

Cancer Vaccines

 

(365,867)

 

 

-

Anti-Viral Therapeutics

 

(309,504)

   

-

Cancer Diagnostics

 

(3,469,673)

 

 

(3,052,355)

Patent Licensing

 

(4,158)

 

 

(971,969)

Total

$

(5,274,565)

 

$

(7,541,543)

           

Total operating costs and expenses

$

5,300,006

 

$

7,826,962

Less non-cash share-based compensation

 

(2,131,420)

 

 

(4,071,614)

Operating costs and expenses excluding
    non-cash share-based compensation

$

3,168,586

 

$

3,755,348

           

Operating costs and expenses excluding non-cash
    share based compensation expense:

 

 

 

 

 

CAR-T Therapeutics

$

570,163

 

$

1,245,681

Cancer Vaccines

 

165,329

 

 

-

Anti-Viral Therapeutics

 

221,018

   

-

Cancer Diagnostics

 

2,208,813

 

 

1,417,967

Patent Licensing

 

3,263

 

 

1,091,700

Total

$

3,168,586

 

$

3,755,348

 

For the Three Months Ended

April 30,

 
 

2020

 

2019

Net loss:

 

 

 

 

 

CAR-T Therapeutics

$

(495,030)

 

$

(1,029,934)

Cancer Vaccines

 

(170,271)

 

 

-

Anti-Viral Therapeutics

 

(309,504)

   

-

Cancer Diagnostics

 

(1,679,027)

 

 

(1,249,001)

Patent Licensing

 

(4,158)

 

 

(296,999)

Total

$

(2,657,990)

 

$

(2,574,934)

           

Total operating costs and expenses

$

2,670,137

 

$

2,843,234

Less non-cash share-based compensation

 

(1,110,086)

 

 

(1,321,450)

Operating costs and expenses excluding
    non-cash share-based compensation

$

1,560,051

 

$

1,521,784

   

 

     

Operating costs and expenses excluding non-cash
    share based compensation expense:

 

 

 

 

 

CAR-T Therapeutics

$

223,822

 

$

444,890

Cancer Vaccines

 

67,059

 

 

-

Anti-Viral Therapeutics

 

221,018

   

-

Cancer Diagnostics

 

1,044,889

 

 

658,433

Patent Licensing

 

3,263

 

 

418,461

Total

$

1,560,051

 

$

1,521,784

 

April 30,

2020

 

October 31,

2019

   

Total assets:

 

 

 

 

 

CAR-T Therapeutics

$

1,011,316

 

$

2,382,460

Cancer Vaccines

 

287,831

 

 

489,881

Anti-Viral Therapeutics

 

384,326

   

-

Cancer Diagnostics

 

4,089,496

 

 

2,921,784

Patent Licensing

 

151,926

 

 

499,568

Total

$

5,924,895

 

$

6,293,693